The stock of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is now priced at $42.16 and the shares are 0.52 points up or 1.25% higher compared to its previous closing price of $41.64. The stock had 168803 contracts set over the past session. FMS shares’ daily volume is compared to its average trading volume at 208003 shares. However, it has a float of 398 million and although its performance was -3.41% over the week, it’s one to watch. Analysts have given the FMS stock a yearly average price target of $37.3 per share. It means the stock’s downside potential is -11.53% with the FMS share price recently placing at $41.46 to $42.22. However, some brokerage firms have priced the stock below the average, including one that has called $37.59.
The shorts are running away from the Fresenius Medical Care AG & Co. KGaA stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the FMS shares have declined. Short interest in the stock represents just 0.11% of its float, but the volume has dropped by 0. The volume of shorted shares dropped to from shares over the last two weeks. The average intraday trading volume has been shares, which means that days to cover moved to roughly.
In the last trading session, Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) dropped by -$1.49 over the week and gained $0.13 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $44.47. The stock recorded its established 52-week high on 07/02/20.
Since 03/20/20, the stock has traded to a low of $29.17 at 44.53%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge.
Looking at current readings, Fresenius Medical Care AG & Co. KGaA’s two-week RSI is 47.4. This suggests that the stock is neutral at the moment and that FMS shares’ price movement remains stable. The stochastic readings are equally revealing at 14.62% meaning the FMS share price is currently in overbought territory.
The technical chart shows that the FMS stock will likely settle at between $42.43 and $42.71 per share. However, if the stock dips below $41.67, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $41.19.
Currently, the stock is trading in the red of MACD, with a reading of -0.97. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Morgan Stanley raised their recommendation for FMS from Underweight to Equal-Weight in May 20 review. Jefferies analysts upgraded their recommendation of the stock from Hold to Buy while keeping its target price at $44.5 in a flash note released to investors on January 21. Barclays seeing the improvements upgraded the stock from Equal Weight to Overweight on June 20.
The average rating for the FMS equity is 2 and is currently gathering a bullish momentum. Of 5 analysts tracking Fresenius Medical Care AG & Co. KGaA polled by Reuters, 2 rated FMS as a hold. The remaining 3 analysts were split evenly. However, the split wasn’t equal as a majority (3) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Elsewhere, the FMS stock price is 17.14X ahead of its 12-month Consensus earnings per share estimates. The stocks P/S ratio currently stands at 18.5below the group’s average of 26.4. Fresenius Medical Care AG & Co. KGaA has its P/E ratio at 1.8, which means that the stock is currently trading at a discount relative to the 4.1 industry average.
Zacks Consensus Estimate forecasts that the current-quarter revenues for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) will increase by about 2.72%, which will see them reach $4.61 billion. The company’s full-year revenues are, however, expected to increase by about 5.49%, up from $17480 million to $18440 million. FMS’s expected adjusted earnings should surge almost 1.96% to end up at $0.52 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -11.55% to record $2.22/share.